CS
BCRX icon

Candriam SCA’s BioCryst Pharmaceuticals BCRX Stock Holding History

Candriam SCA’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.1M Buy
2,514,949
+228,108
+10% +$2.06M 0.11% 169
2026
Q1 		$21.8M Buy
+2,286,841
New +$17.8M 0.11% 180
2015
Q2 		– Sell
-240,000
Closed -$2.17M – 639
2015
Q1 		$2.17M Sell
240,000
-13,000
-5% -$135K 0.04% 378
2014
Q4 		$3.08M Buy
+253,000
New +$2.79M 0.06% 303

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Candriam SCA's BCRX Position: Q2 2026 in Review

Candriam SCA increased its BioCryst Pharmaceuticals (BCRX) stake by 10% in Q2 2026, buying an estimated $2.06M and bringing the position to 2,514,949 shares worth $25.1M. The position accounts for 0.11% of the portfolio, ranked #169.

Candriam SCA first reported a position in BCRX in Q4 2014 and has held it in 4 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Candriam SCA held 2,514,949 shares of BioCryst Pharmaceuticals worth $25.1M as of Q2 2026.
  • Candriam SCA bought 228,108 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $2.06M.
  • BioCryst Pharmaceuticals made up 0.11% of Candriam SCA's portfolio in Q2 2026, its #169 holding.
  • Candriam SCA first reported a position in BioCryst Pharmaceuticals in Q4 2014 and has held it in 4 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.